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X-linked lymphoproliferative disease type 1 (XLP1) is a rare immune deﬁciency caused by mutations in
SH2D1A. Allogeneic hematopoietic cell transplantation (HCT) is often performed because of the morbidity and
mortality associated with XLP1. There is limited experience using reduced-intensity conditioning (RIC) reg-
imens for these patients. Here we report our 8-year single-center experience. Sixteen consecutive patients
diagnosed with XLP1 underwent allogeneic HCT between 2006 and 2013 after a RIC regimen consisting of
alemtuzumab, ﬂudarabine, and melphalan. Patient phenotypes included hemophagocytic lymphohistiocy-
tosis (HLH) after Epstein-Barr virus (n ¼ 5) or human herpesvirus 6 (n ¼ 1), macrophage activation syndrome
(n ¼ 1), interstitial pneumonitis and encephalitis (n ¼ 1), B cell lymphoma (n ¼ 8), and hypogammaglobu-
linemia (n ¼ 2). One patient was asymptomatic. Fourteen of 16 patients received 8/8 HLA-matched unrelated
or related bone marrow grafts, whereas 2 patients received mismatched unrelated grafts. Acute graft-versus-
host disease (GVHD) prophylaxis consisted of methylprednisolone and cyclosporine in all but 1 patient, who
additionally received methotrexate. All patients had hematopoietic recovery. There were no cases of hepatic
veno-occlusive disease or pulmonary hemorrhage. One patient (6%) developed acute GVHD and later also
developed chronic GVHD (6%). Five patients (31%) developed mixed chimerism. Only 1 patient with mixed
chimerism (6%) experienced a decline of donor chimerism to less than 50% but returned to full donor
chimerism after infusion of donor lymphocytes and a CD34þ selected stem cell boost. Infectious complica-
tions were frequent, particularly viral reactivation. One-year survival estimated by Kaplan-Meier analysis was
80%, with long-term survival estimated at 71%. Survival was similar for patients with or without a history of
HLH (86% versus 75%, respectively, P ¼ .70). There were no occurrences of lymphoma or HLH after HCT. RIC
HCT with alemtuzumab, ﬂudarabine, and melphalan is an effective treatment for patients with XLP1, offering
good survival rates regardless of prior disease manifestations, including HLH.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
X-linked lymphoproliferative disease type 1 (XLP1) is a
rare primary immune deﬁciency caused by mutations
in the SH2D1A gene, which encodes the SLAM-associated
protein [1-3]. XLP1 is commonly characterized by fulminant
Epstein-Barr virus (EBV) infection and/or hemophagocytic
lymphohistiocytosis (HLH) after EBV infection as well as B celldgments on page 1645.
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14.06.003lymphoma, hypogammaglobulinemia, aplastic anemia, and
vasculitis [4-7].Allogeneic hematopoietic cell transplantation
(HCT) is often performed to improve reported poor long-term
survival.
Historically, most XLP patients have been transplanted
with a variety of myeloablative conditioning regimens, con-
taining either total body irradiation with cyclophosphamide
or busulfan with cyclophosphamide. In 2005, Lankester et al.
[8] summarized the reported cases to that time (n ¼ 14).
Patients were treated with total body irradiationebased or
busulfan-based myeloablative conditioning regimens in all
but 2 cases. Several regimen-related toxicitieswere observed,
but 71% of patients survived. The authors suggested caution
with consideration of reduced-intensity conditioning (RIC)
regimens, because 1 patient included in their reviewhad died
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darabine, melphalan, and antithymocyte globulin [8].
Since then, increasing numbers of reports have become
available regarding the use of RIC for XLP1. Experiences in
Europe and Japan suggest that survival rates after RIC and
myeloablative conditioning are similar [6,7]. In the largest
series, Booth et al. [7] retrospectively reported the transplant
outcomes for 43 patients transplanted at 22 centers. Patients
transplanted with myeloablative conditioning or RIC regi-
mens experienced similar survival rates of 82.9% and 78.9%,
respectively. However, the authors noted a poor survival of
only 50% among patients with a history of HLH before HCT,
without an obvious impact of conditioning regimen. This is in
contrast to experiencewith familial HLH, where RIC has been
shown to greatly improve patient outcomes [9-11]. Inter-
estingly, Booth et al. also noted 100% survival of patients
without a history of HLH, which is unlikely to translate to all
patients with XLP1 who lack a history of HLH. To gain addi-
tional perspective regarding the outcomes of patients with
XLP1 undergoing RIC HCT, we report here a retrospective
review of our single-center experience with 16 consecutive
patients with XLP1 treated with a RIC regimen consisting of
alemtuzumab, ﬂudarabine, and melphalan.
METHODS
Patients and Transplant Procedures
Sixteen consecutive patients diagnosed with XLP1 were transplanted at
our center between 2006 and 2013 using a RIC regimen consisting of alem-
tuzumab, ﬂudarabine, and melphalan. Patients 1, 2, 4 to 9, 11, and 13 to 15
were also reported previously by Marsh et al. [12]. Conditioning regimens
used in this series have been described in Cooper et al. [10], Shenoy et al. [13],
and Marsh et al. [12], and dosing of alemtuzumab was modiﬁed over the
duration of this report. Alemtuzumab was given either as a dose escalation
schedule of 3 mg/10 mg/15 mg/20 mg or a cumulative 1-mg/kg dose begin-
ning on day 14, 12, 11, or 9, except in 1 patient who, after starting
alemtuzumab, developed acute renal insufﬁciency due to AmBisome (Gilead
Sciences, Inc., San Dimas, CA), and the preparative regimenwas temporarily
halted.After3weeks thepreparative regimenwasagainbegun in thispatient,
and the patient received doses of 10 and 20 mg on days 12 and 11. All
patients received ﬂudarabine 150 mg/m2 divided over days 8 to 4 or 7
to 3, and melphalan 140 mg/m2 on day 3 or 2. Graft characteristics are
shown in Table 1.
Acute graft-versus-host disease (GVHD) prophylaxis consisted of
methylprednisolone 1 to 2 mg/kg and cyclosporine (to maintain goal levels
200 to 350 ng/mL). One patient additionally received methotrexate on
days þ1, þ3, and þ6. Engraftment studies were done using either XY ﬂuo-
rescence in situ hybridization in the case of sex mismatched donor or var-
iable number of tandem repeat analysis in the case of same sex donor in the
clinical genetics laboratory at Cincinnati Children’s Hospital.
Whole blood chimerism studies were performed at the discretion of the
primary physician and as clinically indicated and were initially performed
twice weekly, weekly, or biweekly. Mixed chimerism was deﬁned as whole
blood donor chimerism of less than 95% on 2 or more occasions.
All patients received intravenous immunoglobulin replacement, anti-
fungal prophylaxis, and antiePneumocystis (carinii) jiroveci prophylaxis per
standard institutional practice. In patients with serologic evidence of prior
herpes simplex virus or cytomegalovirus (CMV) or receiving a graft from a
donor with serologic evidence of prior CMV, anti-CMV prophylaxis was also
administered.
Outcomes and Survival Analyses
We retrospectively reviewed themedical records and recorded toxicities
such as hepatic veno-occlusive disease or pulmonary hemorrhage, acute or
chronic GVHD, and infectious complications. We reviewed charts for the
date of last follow-up or death and the cause of death if applicable. Survival
was estimated by generating Kaplan-Meier survival curves using XLSTAT
(Addinsoft, Paris, France). Groups were compared using the log-rank test.
RESULTS
Patients and Transplant Procedures
Sixteen patients were diagnosed with XLP1 after ﬂow
cytometric and/or genetic testing (Table 1). Patientphenotypes included 1 or more of the following: a history of
HLH after EBV (n ¼ 5) or human herpesvirus 6 (n ¼ 1), HLH-
like hyperinﬂammatory presentations includingmacrophage
activation syndrome (n¼ 1) and interstitial pneumonitis and
encephalitis (n ¼ 1), B cell lymphoma (n ¼ 8), and hypo-
gammaglobulinemia (n ¼ 2). One patient was asymptomatic
(diagnosed due to family history). HLH and lymphoma
treatment details are shown in Table 1. One patient (patient
4) had active HLH at the start of the conditioning regimen, as
deﬁned by the presence of fever, pancytopenia, ferritin
>500 ng/mL, elevated soluble IL-2 receptor alpha, and
hemophagocytosis on bone marrow examination during the
2 weeks preceding the start of conditioning. All patients with
a history of lymphoma were in complete remission at the
time of transplantation.
Patients were transplanted after RIC consisting of alem-
tuzumab, ﬂudarabine, and melphalan, as detailed in
Methods. Graft characteristics are summarized in Table 2.
Most patients (14/16) received 8/8 HLA-matched unrelated
or related bone marrow grafts, whereas 2 patients received
either 7/8 or 6/8 HLA-matched bone marrow grafts.
Engraftment and Chimerism
All patients had hematopoietic recovery, with neutrophil
recovery between days 9 and 15 after HCT. Five patients
developed mixed chimerism (31%) at a median of 99 days
after HCT (range, 67 to 117). Because of the small size of the
cohort, we were unable to meaningfully analyze variables
that may have impacted the incidence of mixed chimerism,
such as timing and dose of alemtuzumab, and history of
lymphoma therapies. One patient maintained stable whole
blood donor chimerism greater than 90% at last follow-up
2 years after HCT. Three patients developed stable mixed
chimerism with donor contribution to hematopoiesis above
70% at last follow-up (median follow-up, 868 days; range,
188 to 2393 days) and did not receive any additional
hematopoietic cell products. Whole blood donor chimerism
declined to a minimum of 32% 167 days after HCT in a ﬁfth
patient. This patient received 12 serial donor lymphocyte
infusions, beginning 112 days after HCT, and a CD34þ
selected stem cell boost 200 days after HCT. Whole blood
donor chimerism returned to 95% 300 days after HCT, and he
remains with full donor chimerism at last follow-up
(1406 days after HCT).
Acute Toxicities
There were no occurrences of hepatic veno-occlusive
disease or pulmonary hemorrhage.
Acute and Chronic GVHD
One patient (6%) developed grade III acute GVHD
involving the skin and gastrointestinal tract. No other pa-
tients developed acute GVHD. This same patient later
developed chronic GVHD of the skin and oral cavity, which
had resolved at last follow-up (944 days after HCT).
Infectious Complications after Transplantation
Infectious complications after transplantation were
common. Nine patients developed adenovirus viremia at a
median of 13 days after transplant (range, 7 to 110 days); all 9
received cidofovir. Three patients developed CMV viremia at
amedian of 7 days after HCT (range, 5 to 49 days), and 2were
treated with ganciclovir, foscarnet, and cytogam. One patient
developed quantiﬁable EBV viremia after HCT and was
treated with rituximab, whereas 2 other patients developed
Table 1
Patient Demographics
Patient XLP Phenotype(s) Age at Initial
Presentation (yr)
Site and Stage*
of Lymphoma
Previous HLH,
Inﬂammatory,
or Lymphomay
Treatment
SH2D1A Mutation HLH or
Lymphoma
Disease
Status at HCT
Lansky or
Karnofsky
Performance
Status Score
[14,15]
1 EBV HLH 1 Dex, Etop, IT,
Alem, Ritux
295 C>T (Q99X) Quiescent 20
2 EBV HLH 1 Dex, Etop, CSA,
Alem, Ritux
Gross deletion
including
exon 1, and 346(þ3)
Quiescent 80
3 EBV HLH 1 Dex, Etop, Ritux 95 G>C (R32T) Quiescent 100
4 HHV6 HLH 2 Dex, Etop, IT, CSA 201(þ3) a>g Active 80
5z Asymptomatic Asymptomatic Not applicable 163 C>T (R55X) Not applicable 100
6 Burkitt’s lymphoma 3 Nasopharynx with
cervical LAD
stage II
ANHL01P1-group B
(Cy, Vcr, Dox, MTX,
ARA-c, Pr, Ritux)
Not available Complete
remission
100
7z Burkitt’s lymphoma 3 Left cervical region
and right kidney
stage II
CCG-5961-group B4
(Cy, Vcr, Dox,
MTX, ARA-c, Pr)
163 C>T (R55X) Complete
remission
90
8 EBV HLH 4 Dex, Etop, Ritux Gross deletion
including
exons 1-4
Quiescent 90
9z Burkitt’s lymphoma 6 Ascending colon,
cecum and CNS
stage IV
ANHL-01P1-group C
(Cy, Vcr, Dox, Mtx,
ARA-c, Etop, Pr, Ritux)
163 C>T (R55X) Complete
remission
100
10 Interstitial pneumonitis
and encephalitis
7 Methylprednisolone 195_196 insT
(A66fsX67)
Not applicable 80
11 EBV HLH, Hypogam 2 Dex, Etop, IT 125 G>A (C42Y) Quiescent 100
12 Diffuse large B
cell lymphoma,
2 occurrences,
ages 6 yr and 9 yr
6 Abdominal, cervical
and axillary LAD
stage III
Ascending colon and
mesenteric LAD
stage II
ANHL-01P1-group B
(Cy, Vcr, Dox, MTX,
ARA-c, Pr, Ritux)
ANHL0121
(R-Ifo, Car, Etop)
117 C>T (G39G) Complete
remission
90
13 Large B cell lymphoma,
3 occurrences, ages 3 yr,
5 yr, and 9 yr; Hypogam
3 Large bowel mass
stage III
Perirectal mass
stage II
Right cervical LAD
stage I
CCG-5961-group B3
(Cy, Vcr, Dox, MTX,
ARA-c, Pr)
CCG 5961-
(Cy, ARA-c, Pr, Etop)
CCG 5961-
(Cy, ARA-c, Pr, Etop)
Gross deletion
including exons 2-4
Complete
remission
90
14 Large B cell lymphoma,
macrophage activation
syndrome
1 Left renal, paraspinal
mass and BM
stage IV
POG-9315
(Vcr, Dox, Pr, MTX,
ARA-c, 6-MP)
Methylpred-nisolone,
CSA
Gross deletion
including exons 1-4
Complete
remission
Quiescent
90
15 Burkitt’s lymphoma,
2 occurrences, ages
5 yr and 15 yr
5 Lymph nodal mass
near caecum
stage II
Abdominal mass
stage III
CCG-5961-group A
(Cy, Vcr, Dox, Pr)
ANHL01P1-group B
(Cy, Vcr, Dox, MTX,
ARA-c, Pr, Ritux)
Gross deletion
including exon 2
Complete
remission
100
16 B cell lymphoma 9 Terminal ileum
stage II
CCG-5961-group B
(Cy, Vcr, Dox, MTX,
ARA-c, Pr)
195_196 insT
(A66fsX67)
Complete
remission
100
Dex indicates dexamethasone; Etop, etoposide; IT, intrathecal hydrocortisoneþ/methotrexate; Alem, alemtuzumab; Ritux, rituximab; CSA, cyclosporine; LAD,
lymphadenopathy; Cy, cyclophosphamide; Vcr, vincristine; Dox, doxorubicin; MTX, methotrexate; ARA-c, cytarabine; Pr, prednis(ol)one; Hypogam, hypo-
gammaglobulinemia; CNS, central nervous system; R-Ifo, rituximab plus ifosfamide; Car, carboplatin; BM, bone marrow; 6-MP, 6-mercaptopurine.
* Modiﬁed Murphy staging for childhood non-Hodgkin lymphoma.
y All patients were either enrolled or treated as per Children’s Cancer Group (CCG-5961), Pediatric Oncology Group (POG-9315), and Children’s Oncology
Group (ANHL01P1 and ANHL0121) studies.
z Patients are siblings.
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DNA. BK viremia occurred in 6 patients at a median of
46 days (range, 12 to 85 days) after transplant, with 2
experiencing hemorrhagic cystitis. Human herpesvirus 6
viremia occurred in 2 patients and varicella viremia in 1
patient. Respiratory syncytial virus and human meta-
pneumovirus infections were observed in 1 patient each.
Humanmetapneumovirus was associated with pneumonitis,
respiratory failure, acute respiratory distress syndrome,
and pulmonary thrombotic microangiopathy, and itscontribution to pathogenesis is unclear. Three episodes each
of gram-negative or gram-positive sepsis occurred. One pa-
tient developed P. (carinii) jiroveci pneumonia associated
with respiratory failure (despite appropriate prophylaxis).
Candidemia occurred in 1 patient, and 1 patient developed a
presumed fungal infection of the central nervous system.
Survival
Four of 16 patients died. Three patients died due to in-
fectious complications related to HCT, including human
Table 2
Transplant Information
Patient Age at
HCT (yr)
Donor
Match
Donor
Relation
Stem Cell
Source
Donor
CMV
Patient
CMV
Donor
EBV
Patient
EBV
GVHD Prophylaxis Nucleated Cell
Dose (108/
kg)
1 1.8 8/8 Sibling Marrow  þ (IVIG)* þ þy Cyclosporine and methylprednisolone 12.8
2 1.8 6/8 Unrelated Marrow þ þ (IVIG) þ þy Cyclosporine and methylprednisolone 7
3 2.0 8/8 Unrelated Marrow   þ þy Cyclosporine and methylprednisolone 5.5
4 2.7 8/8 Unrelated Marrow þ þ (IVIG) þ þ (IVIG) Cyclosporine and methylprednisolone 4.7
5z 3.4 8/8 Sibling Marrow     Cyclosporine and methylprednisolone 10.7
6 3.5 8/8 Sibling Marrow þ þ (IVIG) þ þ (IVIG) Cyclosporine and methylprednisolone 11.5
7z 5.1 8/8 Unrelated Marrow  þ (IVIG) þ þ (IVIG) Cyclosporine and methylprednisolone 11.2
8 5.4 8/8 Sibling Marrow  þ (IVIG) þ þy Cyclosporine and methylprednisolone 7.8
9z 6.8 8/8 Sibling Marrow  þ (IVIG)  þ (IVIG) Cyclosporine and methylprednisolone 10
10 8.0 8/8 Unrelated Marrow  þ (IVIG)  þ (IVIG) Cyclosporine and methylprednisolone 3.7
11 10.2 8/8 Unrelated Marrow þ þ (IVIG) þ þy Cyclosporine and methylprednisolone 2.7
12 10.4 8/8 Sibling Marrow  þ (IVIG) þ þ (IVIG) Cyclosporine and methylprednisolone 6.4
13 11.8 8/8 Unrelated Marrow  þ (IVIG) þ þ (IVIG) Cyclosporine and
methylprednisolone,
methotrexate þ1, 3, and 6
5.7
14 12.6 7/8 Unrelated Marrow þ þ (IVIG) þ þ (IVIG) Cyclosporine and methylprednisolone 4.1
15 16.0 8/8 Sibling Marrow  þ (IVIG)  þ (IVIG) Cyclosporine and methylprednisolone 7.1
16 17.7 8/8 Unrelated Marrow  þ þ  Cyclosporine and methylprednisolone 1.5
IVIG indicates intravenous immune globulin.
* Patients with positive serologic testing while receiving IVIG replacement and without positive IgM or PCR testing indicated by (IVIG).
y Positive for EBV by PCR and/or positive IgM antibody.
z Patients are siblings.
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acute respiratory distress syndrome and pulmonary throm-
botic microangiopathy, P. (carinii) jiroveci, and adenovirus
infection together with central nervous system fungal
infection. A fourth patient died more than 2 years after HCT
due to complications of amultivisceral transplant, whichwas
undertaken due to short-gut syndrome that preceded the
HCT and was the result of necrotizing enterocolitis. The
estimated 1-year survival of patients was 80% with no dif-
ference observed between patients with or without a history
of HLH, 86% versus 75%, respectively (P ¼ .70) (Figure 1A).
Long-term survival was estimated at 71% (Figure 1B).Figure 1. (A) One-year survival of patients with or without a history of HLH.
(B) Long-term survival of patients after allogeneic RIC HCT.DISCUSSION
Our experience suggests that alemtuzumab, ﬂudarabine,
and melphalan RIC HCT is an effective preparative regimen
for patients with XLP1 undergoing allogeneic trans-
plantation. Overall, patient survival appears to be similar to
rates reported in patients who received a variety of different
conditioning regimens in the literature, as the 1-year and
long-term survival in our cohort were 80% and 71%, respec-
tively, compared with reports of 71% to 92% [6-8]. Impor-
tantly, we observed that survival appears to be equally good
for patients with and without a history of HLH, although this
observation is limited by the retrospective nature of this
study and the small number of patients. This is in contrast to
the data reported by Booth et al. [7], noting poorer outcomes
for patients with a history of HLH compared with their
observation of 100% survival of patients without a history of
HLH. We previously noted that RIC HCT can as much as
double survival of patients with HLH due to genetic causes
other than mutations in SH2D1A [9]. Coupled with this
experience, the outcomes presented here for patients with
XLP1 suggest that RIC HCT should especially be considered
for patients with XLP1 and a history of HLH. Our experience
also illustrates that patients without a history of HLH are
prone to transplant-related mortality, and a lack of prior HLH
does not necessarily portend survival.
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series and contributed to deaths in all but 1 of the children
who died. As reported previously, adenovirus viremia was
especially common after RIC HCT, occurring in half of pa-
tients, likely as a result of the inclusion of alemtuzumab in
the conditioning regimen. Care should be taken to aggres-
sively monitor patients for viral reactivations in patients
receiving alemtuzumab-containing RIC HCT regimens, and
treatment with antiviral therapies such as ganciclovir, fos-
carnet, cidofovir, brincidofovir, or other treatments should be
considered early for patients with reactivation to prevent
progression to disease, along with continuation or initiation
of standard measures such as intravenous immunoglobulin
replacement and cytomegalovirus immune globulin intra-
venous when appropriate.
Thirty-three percent of patients in this series developed
mixed chimerism, and close monitoring as often as once a
week is helpful to allow early intervention with donor
lymphocyte infusions in cases with marked drops in donor
chimerism. In our series, only 1 patient (6%) experienced a
decline of donor contribution to hematopoiesis to less than
50% and received intervention with donor lymphocyte in-
fusions and CD34þ selected stem cell boost with good effect.
This rate of mixed chimerism appears to be less than that
previously reported for patients with HLH and related dis-
orders, including XLP [12]. It is possible that this difference
reﬂects a change in our practice to dose alemtuzumab at
1 mg/kg beginning on day 14, which 44% of patients in this
series received, in an effort to decrease the incidence of
mixed chimerism as we reported previously [12]. It may also
reﬂect the prior chemotherapy received by 8 patients for
treatment of 1 or more episodes of lymphoma.
We conclude that RIC consisting of alemtuzumab, ﬂu-
darabine, and melphalan is a feasible approach for patients
with XLP1 and appears to result in good outcomes for most
patients, with no relapses of HLH or lymphoma observed in
this series. RIC should especially be considered for patients
with XLP1 who have a history of HLH. The currently evolving
availability of broad-spectrum antivirals and adjunctive
therapies such as virus-speciﬁc cytotoxic T lymphocyte
products will likely continue to further improve patient
outcomes by successful prevention and treatment of com-
mon viral complications. Additionally, future modiﬁcations
to RIC regimens to further decrease the incidence of mixed
chimerism will likely reduce the need for additional he-
matopoietic cell products after HCT and simplify post-HCT
care, which may lead to a more widespread use of this
approach.
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